Novo Holdings
Novo Holdings is a leading life sciences investor and a global asset manager dedicated to generating long-term financial returns for the Novo Nordisk Foundation. It manages a diverse portfolio including investments in life science companies, real estate, bonds, infrastructure, and private equity, with a focus on societal impact and sustainability. The company invests in companies at all stages of development, supporting innovation in healthcare, biotech, and green technologies, and operates from offices worldwide including Copenhagen, San Francisco, Boston, London, Singapore, and Shanghai.
Industries
Nr. of Employees
medium (51-250)
Products
Life Science Investments
Investments in life science companies at all stages, including Seed, Venture, Growth, and Principal Investments, focusing on innovative healthcare solutions.
Capital Investments
Management of a diverse portfolio including equities, bonds, real estate, and infrastructure to generate long-term returns.
Planetary Health Investments
Investments aimed at promoting sustainable solutions and innovations in biotechnology to address environmental challenges.
Life Science Investments
Investments in life science companies at all stages, including Seed, Venture, Growth, and Principal Investments, focusing on innovative healthcare solutions.
Capital Investments
Management of a diverse portfolio including equities, bonds, real estate, and infrastructure to generate long-term returns.
Planetary Health Investments
Investments aimed at promoting sustainable solutions and innovations in biotechnology to address environmental challenges.
Services
Institutional management of a diversified investment portfolio across public and private markets, including capital allocation, portfolio monitoring and performance reporting.
Provision of equity capital and strategic support to life-science companies across stages, including incubation and company-creation at seed stage, and growth capital for commercial acceleration.
Management of non-life-science investments including internally and externally managed public equities, credit, real assets and allocations to private equity and venture funds.
Integration of ESG and societal-impact analysis into pre-investment due diligence, active stewardship through engagement and voting, and transparent reporting at portfolio and exit stages.
Incubation and early-stage investment services, including management of dedicated seed and impact funds and operational support for company creation.
Acquisition and control/co-control investments in healthcare and life-science companies with post-acquisition operational oversight to drive growth and strategic repositioning.
Institutional management of a diversified investment portfolio across public and private markets, including capital allocation, portfolio monitoring and performance reporting.
Provision of equity capital and strategic support to life-science companies across stages, including incubation and company-creation at seed stage, and growth capital for commercial acceleration.
Management of non-life-science investments including internally and externally managed public equities, credit, real assets and allocations to private equity and venture funds.
Integration of ESG and societal-impact analysis into pre-investment due diligence, active stewardship through engagement and voting, and transparent reporting at portfolio and exit stages.
Incubation and early-stage investment services, including management of dedicated seed and impact funds and operational support for company creation.
Acquisition and control/co-control investments in healthcare and life-science companies with post-acquisition operational oversight to drive growth and strategic repositioning.
Expertise Areas
- Multi-stage life-science investment (seed to principal)
- Biotechnology and industrial biosolutions
- Planetary health and green-transition investing
- Clinical development financing and translational support
Key Technologies
- Protein degrader platforms
- Recombinant protein production
- Fermentation and microbial bioprocessing
- Enzyme-based industrial biotechnology
News & Updates
Novo Holdings is pleased to announce the appointment of Dr Joachim Kreuzburg to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its life science investments.
Novo Holdings released its Asia Investments Year in Review 2024, highlighting strategic growth and purpose-driven investing in healthcare, life sciences, and planetary health in Asia.
Novo Holdings led a $130 million Series B financing round for GlycoEra AG, supporting the development of first-in-class IgG4-targeted protein degraders for autoimmune diseases.
Novo Holdings supported Kate Farms, a plant-based clinical nutrition company, which was acquired by Danone. Novo Holdings led Kate Farms’ Series C financing in 2022.
In 2024, Novo Holdings achieved its best performance ever with total income and investment returns of DKK 60 billion (€8.0 billion).
The report highlights strategic growth and purpose-driven investments in Asia, including major milestones and regional expansion.
Novo Holdings is pleased to announce the appointment of Dr Joachim Kreuzburg to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its life science investments.
Novo Holdings released its Asia Investments Year in Review 2024, highlighting strategic growth and purpose-driven investing in healthcare, life sciences, and planetary health in Asia.
Novo Holdings led a $130 million Series B financing round for GlycoEra AG, supporting the development of first-in-class IgG4-targeted protein degraders for autoimmune diseases.
Novo Holdings supported Kate Farms, a plant-based clinical nutrition company, which was acquired by Danone. Novo Holdings led Kate Farms’ Series C financing in 2022.
In 2024, Novo Holdings achieved its best performance ever with total income and investment returns of DKK 60 billion (€8.0 billion).
The report highlights strategic growth and purpose-driven investments in Asia, including major milestones and regional expansion.